Abstract
This manuscript has been withdrawn by the authors due to disagreement with UCSF over data rights.
This withdrawal decision is not related to the validity of the data presented in this study, and these authors understand that this work cannot be cited as reference for the project until the disagreement is resolved.
Competing Interest Statement
F.F. is founder and Chief Scientific Officer of Pano Therapeutics. She is inventor on pending patents that cover methods of use of EIPA, amilorides derivatives and quinine as well as the technology to record and measure NMCC, and holds equity in the company. MZ is Chief Translational Officer of Pano Therapeutics and holds equity in the company. DW is scientific advisor to Pano Therapeutics, Inc. and advisor to Medical Excellence GP, LLC